NCT02353715View on ClinicalTrials.gov

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

July 7, 2015

Primary Completion Date

November 14, 2018

Study Completion Date

November 14, 2018

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

DRUG

Abiraterone acetate

DRUG

Sipuleucel-T

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT02353715 - Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing | Biotech Hunter | Biotech Hunter